Check all that apply
Established in 2020 by
BD Contact
Summary
Viral diseases represent a serious health threat, exemplified by the recent COVID-19 pandemic. Moreover, viral diseases, such as Dengue, West Nile, and Zika fevers exact a particularly significant toll in the developing world. Relying on the results of two decades of research, ViroBlock plans to target and exploit a particular vulnerability in the viruses that cause these diseases: ion channels. Channels are critical components of the pathogen that enable it to regulate its salinity and acidity. Consequently, inhibiting such channels is a promising and validated route to curb viral infectivity. In particular, ViroBlock developed rapid screening approaches that can identify inhibitors from thousands of chemicals in a matter of weeks. Finally, focusing the screen on a library of approved drugs (repurposing) shortens the regulatory approval time dramatically, while lowering the risk.
Established in 2017 by
BD Contact
Summary
Tissue Dynamics bionic microtissues are three dimensional human organoids embedded with electro optical sensors that provide critical insight into human-relevant mechanisms. These proprietary physiological models are powered by unprecedented AI & automation capabilities.Â
Established in 2020 by
BD Contact
Summary
Developer of a medical navigational tool designed to reduce the length of ERCP procedure. The company’s tool helps in preventing inflammation that can be caused during the procedure if the catheter is accidentally inserted into the pancreas duct, rather than the gallbladder duct, enabling surgeons to accurately diagnose and treat patients suffering from bile duct blockage.
Established in 2016 by
BD Contact
Summary
SpliSense is an Israel-based company focused on transformative RNA-based treatments. Our pioneering platform harnesses Antisense Oligonucleotides (ASOs) for treatment of genetic diseases such as Cystic Fibrosis and pulmonary diseases. Our innovative approach targets unmet needs in pulmonary diseases. SpliSense aims to target the root cause of the disease, to overcome specific genetic mutations and restore protein function.
Established in 2020 by
BD Contact
Summary
Established in 2020 by
BD Contact
Summary
Senseera’s technology ushers a new generation of liquid biopsy blood tests providing unparalleled information about disease processes in the patient’s internal organs and immune system with a single blood test. Senseera’s mission is to transform disease diagnosis and treatment and to enhance development of new therapeutics.
Â
Established in 2017 by
BD Contact
Summary
Established in 2016, Salignostics has developed a novel technology which utilizes saliva for lateral flow immunoassay applications. Our vision is to transform the next generation of in-vitro diagnostics by developing easy, clean, safe, low-cost, accessible and reliable saliva-based products.
Established in 2013 by
BD Contact
Summary
Raziel Therapeutics is advancing the science of fat removal treatments by harnessing the body’s natural healing mechanism. Backed by leading investors, we build on science developed at the Hebrew University in Jerusalem. Raziel is currently running several clinical studies for diverse fat disorder indications as well as for aesthetics.
Established in 2020 by
BD Contact
Summary
Pigmentum is an Israeli agro-tech company established in 2018. Tal Lutzky (CEO) and Amir Tiroler (CTO) just completed their agronomy studies in Robert H. Smith School of Agriculture at the Hebrew University of Jerusalem’s (Rehovot campus), when they came up with the concept of an inducible mechanism in transgenic plants. With the support of Prof. Alexander (Sasha) Vainstein, a world expert in plants genomics and metabolic engineering they developed the company’s proprietary technology.
While originally designated for drawing unlimited patterns for personalizing decorative live plants, they soon realized the full potential of their development, for high scale production of natural compound for the food, pharma and cosmetic industries.
Â
Established in 2014 by
BD Contact
Summary
Pepticom designs novel peptide drug candidates, utilizing unique biocomputational AI software, to optimize the discovery process, accelerate time to market and reduce development risks and costs. Our mission is to advance 21st century medicine by improving access to novel peptide therapeutics. We harness the power of AI to design the best peptide drugs possible by expanding the exploration process to uncharted chemical space.
Hi-Tech Park, Edmond J. Safra
Campus, Bungalow 2.6
Givat-Ram, Jerusalem
P.O. Box 39135
91390 Israel